Mpox vaccine for adolescents and eight new medicines obtain EMA approval  – Euractiv

The European Medicines Company’s (EMA) human medicines committee has authorised the usage of Bavarian Nordic’s mpox vaccine Imvanex for adolescents. 

The suggestion is predicated on the interim outcomes of a examine which discovered that adolescents had an analogous immune response to the vaccine as adults. 

The extension of the therapeutic indications to adolescents is a crucial improvement as younger persons are significantly susceptible to the illness in the event that they turn out to be contaminated.  

Up till now, the vaccine might solely be used “off-label” in adolescents, the place the advantages of vaccination outweigh the potential dangers. 

On 13 September, the World Well being Organisation (WHO) introduced that the vaccine had certified for its pre-qualification listing, an essential step that led GAVI to make an advance buy of 500,000 doses of Imvanex, often known as Jynneos. The doses shall be delivered by GAVI’s accomplice, UNICEF.  

WHO helps the usage of a single dose slightly than a second dose as knowledge reveals that even one dose is 76% efficient at defending folks from mpox. This may assist constrained provides attain a wider inhabitants.   

COVID-19 updates, market authorisation for brand new medicines accepted

The Committee for Medicinal Merchandise for Human Use (CHMP) gave constructive suggestions for 2 mRNA COVID-19 vaccines (Spikevax and Comirnaty) which were up to date to focus on the JN.1 variant and KP.2 substrain. The EMA beneficial these changes in July.   

The CHMP additionally beneficial eight new medicines for approval and beneficial the extension of the therapeutic use of 11 different medicines.  

The listing contains most cancers medicines (Elahere for ovarian most cancers, Hetronifly for small-cell lung most cancers, Pomalidomide Teva for a uncommon bone marrow most cancers), two biosimilars for age-related macular degeneration (Afqlir and Opuviz) and a drugs to deal with two sorts of haemophilia (Hympavzi).  

The CHMP’s subsequent assembly is scheduled for 14–17 October. 

[Edited by Daniel Eck]

Learn extra with Euractiv


Leave a Reply

Your email address will not be published. Required fields are marked *